Nasal cells drive differences in cold severity

Scientists have discovered that the body's rapid response in nasal cells largely determines whether a rhinovirus infection leads to a mild cold or more severe symptoms. Using lab-grown human nasal tissue, researchers showed how interferons coordinate defenses to contain the virus early. The findings, published January 19 in Cell Press Blue, emphasize the role of host responses over viral traits alone.

Rhinovirus, the leading cause of common colds, triggers an immediate defense in the nasal passages upon entry. Cells lining the nose activate antiviral mechanisms to limit the virus's spread, according to a study led by Ellen Foxman of Yale School of Medicine. This early reaction often decides if symptoms develop and their intensity, particularly in individuals with asthma or chronic lung conditions.

To investigate, the team developed organoids from human nasal stem cells, cultured for four weeks with air exposure on the upper surface. This created a multilayered tissue mimicking the nasal lining, complete with mucus-producing cells and ciliated cells that clear debris. "This model reflects the responses of the human body much more accurately than the conventional cell lines used for virology research," Foxman noted, highlighting its value for studying a human-specific virus like rhinovirus.

Experiments revealed that upon detection, infected cells release interferons—proteins that alert nearby healthy cells to bolster defenses against viral replication. A swift interferon response confines the infection, preventing symptoms. Blocking this pathway allowed the virus to proliferate, damaging tissue and even killing organoids in some cases. "Our experiments show how critical and effective a rapid interferon response is in controlling rhinovirus infection, even without any cells of the immune system present," said first author Bao Wang.

If the virus evades initial controls and replicates, it activates sensors prompting excessive mucus production and inflammation in both infected and uninfected cells. These responses contribute to airway issues and breathing difficulties. The researchers suggest targeting such pathways could yield treatments that enhance defenses while curbing harmful inflammation.

While the model lacks the full diversity of human tissues, including immune cells, it underscores that host factors are pivotal in illness outcomes. "Our study advances the paradigm that the body's responses to a virus, rather than the properties inherent to the virus itself, are hugely important in determining whether or not a virus will cause illness and how severe the illness will be," Foxman concluded. Future studies will explore additional cell interactions and environmental influences.

Articoli correlati

Realistic microscopic illustration of influenza viruses surfing along a human cell membrane before entry.
Immagine generata dall'IA

Scientists film influenza viruses ‘surfing’ into human cells in real time

Riportato dall'IA Immagine generata dall'IA Verificato

An international team led by ETH Zurich and including researchers in Japan has used a new high‑resolution imaging technique to watch, live, as influenza viruses penetrate human cells. The work shows that cells actively engage with the virus, helping to draw it inside in a process that resembles surfing along the cell membrane, and could inform the development of targeted antiviral therapies.

Researchers at Stanford Medicine have created an experimental nasal spray vaccine that protects mice against multiple respiratory threats, including COVID-19, flu, bacterial pneumonia, and allergens. The vaccine activates the lungs' innate immune system for months, offering broad defense without targeting specific pathogens. Published in Science on February 19, the study suggests potential for human trials soon.

Riportato dall'IA

Scientists have identified the oldest confirmed human RNA virus in lung tissue from a woman who died in London around the 1770s. The rhinovirus, which causes the common cold, was reconstructed from fragmented genetic material preserved in alcohol. This discovery opens new possibilities for studying the evolution of RNA viruses in human history.

Scientists have harvested antibodies from the blood of paediatricians to develop new preventative treatments for respiratory syncytial virus (RSV) and human metapneumovirus. These antibodies outperform existing therapies by up to 25 times and target a wider range of strains. The discovery stems from the natural immunity built by paediatricians through years of exposure to respiratory viruses.

Riportato dall'IA Verificato

Mayo Clinic researchers have mapped a molecular circuit in alveolar type 2 lung cells that helps determine whether they rebuild tissue or fight infection. The study, published Oct. 14, 2025, in Nature Communications, suggests new paths for regenerative approaches in chronic lung conditions such as pulmonary fibrosis and COPD.

A team of microbiologists suggests that infections occurring alongside SARS-CoV-2 may contribute to some cases of long COVID, potentially by reactivating latent pathogens such as Epstein–Barr virus or altering the course of tuberculosis. Their perspective, published in eLife, stresses that this remains a hypothesis and calls for large studies and better animal models to test whether these co-infections help drive persistent symptoms like fatigue and brain fog.

Riportato dall'IA Verificato

Chronic inflammation reshapes the bone marrow niche, fostering the expansion of mutated blood stem cells seen in clonal hematopoiesis and early myelodysplasia. The work, published November 18, 2025 in Nature Communications, maps a feed‑forward loop between inflammatory stromal cells and interferon‑responsive T cells and points to therapies that target the microenvironment as well as mutant cells.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta